Does Avita Medical have a bright future?

One company that recently caught our attention, that I believe is worth monitoring, is Avita Medical (ASX:AVH). AVH owns the patents and produces a medical device called RECELL, which produces a “suspension” of spray-on skin cells using a small sample of the patient’s own skin to help treat burn patients and skin defects.

The sample contains the cells necessary to regenerate the outer layer of skin and is applied at point-of-care (at the hospital – an important distinction versus competitors). The primary purpose of RECELL initially will be to treat patients with acute and severe burns.

The device was invented by Australian of the Year Dr Fiona Wood and has been used to treat victims of the 2002 Bali bombings.

The company has been listed since 2002 but has suffered numerous setbacks to commercialisation – including delays to clinical trials required for regulatory approval – while racking up losses and raising capital along the way.

A major turning point appears to have occurred in 2015, when AVH was able to secure significant funding from the US Biomedical Advanced Research and Development Authority (BARDA) to help fund development efforts to secure pre-market approval for RECELL by the Food and Drugs Administration (FDA) in the US. In September 2018, the company received FDA approval for the use of RECELL to treat patients over the age of 18 with acute and severe burns, paving the way to commence commercial activities in the largest market.

To understand the benefits of the RECELL device, it is important to look at the clinical trial results. The current standard of care for severe burn patients is based on skin grafting techniques; the RECELL device significantly reduces the donor skin requirement with no compromising impacts on efficacy. For larger burn areas, the skin requirement is reduced in combination with traditional grafting, where surgeons have used “spray-on” skin between gaps on wider areas for successful surgical outcomes.

RECELL trials have demonstrated improved patient outcomes including shorter length of stay, reduced pain and improved cosmetic outcomes (less scarring), while hospitals have benefited from lower treatment costs and improved productivity.

In April 2019, RECELL was showcased in numerous presentations at the major ABA Burns Conference in the US, which featured analysis on significant cost-saving outcomes for AVH’s target patient market (i.e. patients with a total burns surface area more than 10 per cent). The increased awareness of the product should help drive adoption in a market that is relatively concentrated (134 burn centres, 300 burn surgeons) over the next few years.

While AVH’s initial target market appears to be somewhat limited in terms of the total addressable market (AVH estimates of ~US$200 million based on burn centre in-patients in the US), there appears to be additional opportunities for application of the RECELL technology. There are various stages of trials and development including:

  • Approval for use for Paediatrics – where trials have commenced in late 2018. AVH has already used the device on paediatrics in previous trials for compassionate use
  • Chronic wounds – including venous leg and diabetic foot ulcers
  • Hypopigmentation – vitiligo and scars
  • Trauma wounds

There is also the opportunity to partner with other companies to penetrate new geographies (as evidenced by its recent deal with COSMOTEC in Japan).

Source: Company presentations

Given sales roll-out is at a very early stage, one major risk for AVH is execution and wide-spread adoption. Despite 26 of 134 burn centres already having placed orders for RECELL, adoption of new medical devices takes time, including training of staff and evaluation of the product by a hospital’s value analysis committee. This impacts the trajectory of sales revenue and path to profitability.

There is also significant time and money invested in clinical trials and regulatory processes (as well as risk on approvals) – albeit for burns indications for paediatrics appears somewhat mitigated by BARDA’s funding of trials and pre-existing approvals for adults.

2 topics

1 stock mentioned

Joseph Kim
Portfolio Manager

Joseph is a Portfolio Manager for the Listed Equities Portfolio at Washington H. Soul Pattison. Prior to this he was Portfolio Manager of The Montgomery Fund – a high conviction all-cap Australian equity fund and also Head of Fundamental Research...

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.


Please sign in to comment on this wire.

trending on livewire
Get the best of Livewire by signing up to our popular daily newsletter